Skip to main content
OpenTrials
Completed

NCT Number: NCT02572648

A Comparison of Magnetic Resonance Imaging in Persons With Heart Failure to Health, Aged Matched Controls

The purpose of this study is to examine the relation between the structural brain changes associated with heart failure, neurocognitive performance, and how these changes impact self-care behaviors.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Emory St. Joseph's Hospital, Atlanta, Georgia, United States

Loading trial locations.

About this study

The purpose of this study is use neuroimaging techniques to better understand the underlying structural brain changes and physiological mechanisms that guide the thinking and decision making processes required for people with heart failure. The study will compare how the underlying brain structures and circulation are similar to or different in persons with heart failure to healthy, aged matched controls using special neuroimaging procedures.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants with heart failure:

  • Speak and understand English
  • Live independently within a 60 mile radius of Atlanta
  • Montreal Cognitive Assessment (MOCA) score of less than or equal to 24
  • Documented medical diagnosis of New York Heart Association (NYHA) class II or III systolic
  • Left ventricular ejection fraction (LVEF) greater than or equal to 10% that is documented within the last year by echocardiogram, cardiac catheterization ventriculography, or radionuclide ventriculography
  • Receiving medication therapy for heart failure (HF) according to American College of Cardiology (ACC) American Heart recommendation guidelines for at least 8 weeks prior to study enrollment

Healthy Controls

  • Speak and understand English
  • Live independently within a 60 mile radius of Atlanta

Exclusion criteria

Participants with heart failure:

  • New York Heart Association (NYHA) class I or IV
  • Change in heart failure (HF) therapy within 6 months
  • Worsening of heart failure (HF) symptoms within last 5 days
  • Unstable angina
  • Renal insufficiency (serum creatinine greater than 3.o mg/dL)
  • Hospitalized within the last 30-days
  • Diagnosed with any neurological disorder that may interfere with cognitive function
  • Beck Depression Inventory II (BDI-II) score greater than 25
  • Claustrophobia
  • Implanted devices such as internal cardiac defibrillator or pacemaker
  • Carrying non-removable objects
  • Stents
  • Body weight more than 120 kg

Healthy Controls

  • Taking prescription medications
  • Cardiovascular disease;
  • Cerebrovascular disease
  • Neurological disease
  • Respiratory disease
  • Claustrophobia
  • Any implanted metal objects not considered safe or appropriate for the MRI environment.

Treatment and study plan

Brain Imaging (Neuroimaging)

Other

Magnetic Resonance Imaging (MR) will be acquired on a research dedicated Siemens 3Tesla TIM TRIO MRI scanner with a 32-channel head coil.The MRI scanning protocol will have scans to measure voxelwise and whole-brain measures of grey matter (GM) volumes through a high resolution T1-weighted (T1W) multi-echo magnetization prepared gradient echo (MEMPRAGE) anatomic scan.

Total time in scanner will be approximately 53 minutes.

Cognitive Function Assessment

Other

Cognitive function will be assessed using several batteries; the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled Oral Word Association Test (COWA), the Color Trails 1 & 2, the WAIS-III Digit Span and Letter Number Sequence test, the Stroop Test, and the California Computerized Assessment Package Reaction Time test (CALCAP).

Primary outcomes

  1. Structural White Matter

    Time frame: Visit 1 (Up to 2 hours)

    Diffusion tensor imaging (DTI) and myelin water imaging (MWI) will be used to compare brain structural white matter between participants with heart failure and healthy controls. This will be obtained via magnetic resonance imaging (MRI) techniques.

Secondary outcomes

  1. Functional Connectivity

    Time frame: Visit 1 (Up to 2 hours)

    Functional connectivity that regulates neurocognitive functions will be assessed by blood oxygen level dependent resting state functional MRI (rsFMRI).This will be obtained via magnetic resonance imaging (MRI) techniques.

  2. Global Cerebral Blood Flow (CBF)

    Time frame: Visit 1 (Up to 2 hours)

    Arterial spin labeling (ASL) based magnetic resonance (MR) perfusion imaging will evaluate global cerebral blood flow (CBF). This will be obtained via magnetic resonance imaging (MRI) techniques.

  3. Regional Cerebral Blood Flow (CBF)

    Time frame: Visit 1 (Up to 2 hours)

    Arterial spin labeling (ASL) based magnetic resonance (MR) perfusion imaging will evaluate regional cerebral blood flow (CBF). This will be obtained via magnetic resonance imaging (MRI) techniques.

  4. Structural Grey Matter

    Time frame: Visit 1 (Up to 2 hours)

    Voxel-based morphometry (VBM) of T1-weighted (T1w) high-resolution magnetic resonance imaging MRI anatomics will be used to measure brain structural white matter.

  5. Cognitive Function assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    Time frame: Visit 2 (Up to 2 hours)

    The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a brief, individually administered test designed to evaluate neuropsychological status of adults, ages 20-89. The 12 subtests measure attention, language, visuospatial/constructional abilities, and immediate and delayed memory.

  6. Cognitive Function assessed by the Controlled Oral Word Association (COWA) Test

    Time frame: Visit 2 (Up to 2 hours)

    The Controlled Oral Word Association (COWA) Test is a verbal fluency test that measures spontaneous production of words belonging to the same category or beginning with some designated letter. The more words produced in the allotted time period the higher the score.

  7. Cognitive Function assessed by the Color Trails Test

    Time frame: Visit 2 (Up to 2 hours)

    The Color Trails Test measures sustained attention and sequencing. For Part 1, the respondent uses a pencil to rapidly connect circles numbered 1-25 in sequence. For Part 2, the respondent rapidly connects numbered circles in sequence, but alternates between pink and yellow. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors.

  8. Cognitive Function assessed by the Wechsler Adult Intelligence Scale-III (WAIS-III) Digit Span Test

    Time frame: Visit 2 (Up to 2 hours)

    The Wechsler Adult Intelligence Scale-III (WAIS-III) Digit Span Test measures short-term memory, attention, and concentration. Participants will be asked to repeat 3 - 9 digits forward and 2 - 9 digits backwards.

  9. Cognitive Function assessed by the Wechsler Adult Intelligence Scale-III (WAIS-III) Letter Number Sequence Test

    Time frame: Visit 2 (Up to 2 hours)

    During the Wechsler Adult Intelligence Scale-III (WAIS-III) Letter Number Sequence Test, participants will be presented with combinations of letters and numbers, (two to nine letter-number combinations). Participants will be asked to repeat each series by, first, repeating the numbers in ascending order, then the letters in alphabetical order. The test measures working memory or the ability to simultaneously recall and organize stimuli of different and similar types

  10. Cognitive Function assessed by the Stroop Test

    Time frame: Visit 2 (Up to 2 hours)

    The Stroop Test measure a person's selective attention capacity and skills, as well as their processing speed ability.It is used to examine a person's executive processing abilities. The Stroop Test during brain imaging studies is used to investigate regions of the brain that are involved in planning, decision-making, and managing real-world interference

  11. Cognitive Function assessed by the California Computerized Assessment Package (CALCAP)

    Time frame: Visit 2 (Up to 2 hours)

    The California Computerized Assessment Package assesses reaction times, speed of information processing, rapid visual scanning, form discrimination, brief memory and divided attention.

  12. Self-Management assessed by the Self-care Index Heart Failure (SCHFI)

    Time frame: Visit 2 (Up to 2 hours)

    The Self-care Index Heart Failure (SCHFI) is a measure designed to assess self-care maintenance, management, and confidence. Participants will be asked to recall feelings of the aforementioned in the last three months.

  13. Peak oxygen consumption assessed by the Modified Balke Test

    Time frame: Visit 2 (Up to 2 hours)

    Peaked oxygen consumption will be assessed by the Modified Balke Test. Participants will be asked to walk on a slightly inclined treadmill. The amount of oxygen consumed will be measured while walking for up to ten minutes.

  14. Quality of Life assessed by the Kansas City Cardiomyopathy Questionnaire

    Time frame: Visit 2 (Up to 2 hours)

    The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.

Sponsors and collaborators

Lead sponsor

Emory University

Other

Collaborators

  • National Institute of Nursing Research (NINR)

Registry information

Official study title

A Comparison of Magnetic Resonance Imaging in Persons With Heart Failure to Health, Aged Matched Controls (MIND-HF)

Acronym: MIND-HF

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Oct 9, 2015
Registry last updated
Sep 21, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.